This narrative illuminates need for students and clinicians to be well prepared to face ethically and structurally complex realities of identifying and responding to children.
AMA J Ethics. 2023;25(2):E159-165. doi:
10.1001/amajethics.2023.159.
Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.